Skip to main content

Breadcrumb

  1. Home

Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)

Establishment of Functional MRI Imaging Parameters for Use in the Evaluation of Sickle Cell Disease

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Establishment of Functional MRI Imaging Parameters for Use in the Evaluation of Sickle Cell Disease

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

Treatment of Acute Lymphoblastic Leukemia in Children

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Treatment of Acute Lymphoblastic Leukemia in Children

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy

Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 15:18
  • Read more about Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 160
  • Page 161
  • Page 162
  • Page 163
  • Page 164
  • Page 165
  • Page 166
  • Page 167
  • Page 168
  • …
  • Next page Next
  • Last page Last
Subscribe to